The ALS Society of Canada (ALS Canada) is proud to once again partner with Mitsubishi Tanabe Pharma Canada to support promising advancements in ALS care through the 2024 Mitsubishi Tanabe Pharma Canada Fellowship. This fellowship funds individuals dedicated to improving clinical care for people living with ALS while furthering their research training.
The 2024 recipient, Dr. Béatrice Soucy, is receiving a one-year fellowship of $100,000 to support her research at the University of Calgary under the supervision of Dr. Gordon Jewett, a past fellowship recipient.
“We are grateful to Mitsubishi Tanabe Pharma Canada for their continued partnership, which strengthens our ability to support early career researchers,” says Dr. David Taylor, Vice-President of Research and Strategic Partnerships at ALS Canada. “With Dr. Jewett now mentoring Dr. Soucy, this fellowship demonstrates how sustained investment builds expertise, drives discoveries, and advances clinical care for people affected by ALS.”
Dr. Soucy’s research focuses on understanding the unique needs of people whose ALS primarily affects arm and hand movement. She aims to explore how their priorities differ from those of other people living with the disease and how addressing these specific challenges can improve symptom management and quality of life.
Her work will help develop new care pathways that better align with patient needs. After her fellowship, Dr. Soucy aims to bring this research and training to a long-term role at the Université de Montréal Hospital Centre (CHUM) as she works toward specializing in ALS rehabilitation care.
To learn more about Dr. Soucy’s research here. For more information about the ALS Canada Research Program, visit als.ca/research/our-research-program
You can make a difference.
Donations allow people living with ALS to receive one-on-one guidance and in-home assistance, access to life-enhancing equipment, and have compassionate community support.